Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.

BMC cancer - 3 Mar 2022

Kim Eugene, Jiang Yanwen, Xu Tao, Bazeos Alexandra, Knapp Andrea, Bolen Christopher R, Humphrey Kathryn, Nielsen Tina G, Penuel Elicia, Paulson Joseph N

Abstract excerpt

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defined using a number of well-established molecular subsets. Application of non-negative matrix factorization (NMF) to whole exome sequence data has previously been used to identify six distinct molecular clusters in DLBCL with potential clinical relevance. In this study, we applied NMF-clustering to targeted sequencing data utilizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Enhancer of Zeste Homolog 2 Protein

Share to Lymphoma, Large B-Cell, Diffuse

Share to Proto-Oncogene Proteins c-bcl-2

Share to RNA-Seq

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 35236331
DOI: 10.1186/s12885-022-09237-5
PMCID: PMC8892802

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.PMID 35236331Read ↗

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.Semantic proximity Read ↗

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?Semantic proximity Read ↗

High-risk subgroup and associated genes identified by next generation sequencing in diffuse large B cell lymphoma.Semantic proximity Read ↗

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaSemantic proximity Read ↗

Molecular classification and therapeutics in diffuse large B-cell lymphomaSemantic proximity Read ↗

Prediction of Overall Survival Status of Diffuse Large B-Cell Lymphoma Using a Prognostic Classification ModelSemantic proximity Read ↗

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA StudySemantic proximity Read ↗

Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic LymphomaSemantic proximity Read ↗

Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.Semantic proximity Read ↗

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.